Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003462priorityCriticalpatent/ECSP003462A/en
Publication of ECSP003462ApublicationCriticalpatent/ECSP003462A/en
Se describe el uso de un interferón-alfa pegilado, y el antagonista CCR5, adicionalmente en asociación con por lo menos uno de ribavirina, IL-2, IL-12, pentafusida sola o en combinación con una terapia de droga anti HIV-1, por ejemplo HAART, para la preparación de un medicamento para el tratamiento de infecciones de HIV-1 asi como también infecciones de HIV-1 como asi también co-infecciones de HIV-1 y HCV en pacientes adultos y pediátricos que no han sido sometiods a tratamiento, asi como también pacientes adultos y pedriáticos que han experimentado tratamiento.The use of a pegylated interferon-alpha, and the CCR5 antagonist, is described, additionally in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with anti-HIV-1 drug therapy, for example HAART, for the preparation of a medicine for the treatment of HIV-1 infections as well as HIV-1 infections as well as co-infections of HIV-1 and HCV in adult and pediatric patients who have not undergone treatment, as well as adult and pediatric patients who have undergone treatment.
USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C
PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.